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In the treatment of breast cancer, combination chemotherapy is used to overcome drug resistance. Combining doxorubicin and
vinorelbine in the treatment of patients with metastatic breast cancer has shown high response rates; even single-agent vinorelbine in
patients previously exposed to anthracyclines results in significant remission. Alterations in protein kinase-mediated signal transduction
and p53 mutations may play a role in drug resistance with cross-talk between signal transduction and p53 pathways. The aim of this
study was to establish the effects of doxorubicin and vinorelbine, as single agents, in combination, and as sequential treatments, on
signal transduction and p53 in the breast cancer cell lines MCF-7 and MDA-MB-468. In both cell lines, increased p38 activity was
demonstrated following vinorelbine but not doxorubicin treatment, whether vinorelbine was given prior to or simultaneously with
doxorubicin. Mitogen-activated protein kinase (MAPK) activity and p53 expression remained unchanged following vinorelbine
treatment. Doxorubicin treatment resulted in increased p53 expression, without changes in MAPK or p38 activity. These findings
suggest that the effect of doxorubicin and vinorelbine used in combination may be achieved at least in part through distinct
mechanisms. This additivism, where doxorubicin acts via p53 expression and vinorelbine through p38 activation, may contribute to
the high clinical response rate when the two drugs are used together in the treatment of breast cancer.
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Anthracyclines are one of the most active agents in
primary adjuvant and palliative treatment of breast cancer (Kroger
et al, 1999). In metastatic breast cancer, response rates to single
doxorubicin treatment range from 52% in previously untreated
patients to 28% in patients previously exposed to an alkylating
agent (Perry, 1996; Esteva et al, 2001). Vinorelbine single-agent
treatment of metastatic breast cancer achieves response
rates of 35–45% as first-line and 15–30% as second-line
therapy (Fumoleau et al, 1995; Burstein et al, 2001). Despite prior
exposure to anthracycline therapy, patient remission was obtained
in up to 47% using vinorelbine as a single agent, and for
anthracycline-resistant cancers a response rate of 16% was still
achieved (Kroger et al, 1999). However, the development of
drug resistance in cancer cells, particularly against single
agents, results in incomplete responses to chemotherapy (Jensen
et al, 1999; Coley et al, 2000; Stavrovskaya, 2000). Com-
bined vinorelbine and doxorubicin treatment for metastatic
breast cancer has shown higher (74%) overall response rates
compared to single-agent treatment (Tsuruo et al, 1994; Fumoleau
et al, 1995; ESMO, 2000), suggesting a synergistic effect of the two
drugs.
A detailed knowledge of the mechanisms of action of
chemotherapy agents such as doxorubicin and vinorelbine remains
incomplete. Two possible routes include signal transduction
pathways and the p53 pathway.
Signal transduction is involved in coordinating the cellular
response to environmental stresses and is one of the fundamental
processes of living cells (Dhanasekaran, 1998; Davis, 2000; Jordan
et al, 2000; Liem et al, 2002). Through these pericellular
communications, embryological cells grow, migrate and differ-
entiate, and adult cells maintain their cellular integrity through cell
proliferation (cell cycle progression) or cell death (apoptosis) in
response to external stimuli (Pawson, 1995; Wang et al, 1998;
Maemura et al, 1999).
Within the mitogen-activated protein kinase (MAPK) family,
function of the extracellular signal regulated kinase (ERK, here
referred to as MAPK) and p38 appear to be coordinated with JNK
in mammary epithelial cells (Agarwal et al, 2000; Finlay et al,
2000).
p53 is a key gene involved in tumour response to therapy,
integrating cellular stress including the action of chemotherapy
agents resulting in a range of responses including cell cycle arrest
and apoptosis (Hupp et al, 2000; Vogelstein et al, 2000; Ziyaie et al,
2000).
In drug resistance, cross-talk between alterations in signal
transduction pathways and the p53 gene has been suggested
(Agarwal et al, 2001). To identify whether either of these pathways
might be relevant in the treatment of breast cancer, this study was
performed to establish the effect of doxorubicin and vinorelbine
on signal transduction and p53 expression.
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Cell culture
MDA-MB-468 and MCF-7 human breast cancer cell lines were
obtained from the American Type Culture Collection and cultured
in 5% CO2 at 371C using Dulbecco’s modified Eagle’s medium,
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. All experiments were performed in triplicate.
Treatments
MTT cytotoxicity assays (Table 1) were performed for doxorubicin
and vinorelbine. Using the IC50 value for vinorelbine and
doxorubicin, MDA-MB-468 and MCF-7 were treated for a total of
4h. While maintaining the vinorelbine treatment for 3h, doxorubicin
was added either 1h before (pretreatment with doxorubicin), 1h
after (pretreatment with vinorelbine), or at the same time (combined
treatment). Single-agent controls were set up in parallel with pre-
and combined treatment regimes. Mitogen-activated protein kinase
and p38 activities were determined by kinase assay for the
appropriate substrate. p53 expression was determined by Western
blotting following treatment for 4 and 24h with both drugs using
IC30 values as single agent or in combination.
Mitogen-activated protein kinase and p38
immunoprecipitation
Following treatment, cells were washed in ice-cold PBS and
harvested by mechanical dislodging using a disposable cell scraper
(Sarstedt Inc.) in the presence of cell lysis buffer (NEBS),
supplemented with phenylmethylsulfonylfluoride for 5min. The
cell lysates were sonicated on ice (Soniprep 150, Sanyo) at full
amplitude for four 5s bursts and centrifuged at 13000r.p.m. for
10min at 41C. Protein levels were determined spectrophotome-
trically within the supernatants and 200ml cell lysates (containing
200mg total protein) were incubated overnight at 41C with 15mlo f
immobilised phospho-p44/42 MAPK monoclonal antibody or 20ml
of immobilised phospho-p38 MAPK monoclonal antibody for the
MAPK and p38 assay, respectively.
Protein kinase assays and Western blot analysis
Following incubation, the suspensions were microcentrifuged at
13000 r.p.m. at 41C for 10min and washed in 500mlo f1 lysis
buffer and 500mlo f1 kinase buffer. Pellets were suspended in
50mlo f1 kinase buffer supplemented with 200mM ATP and 2mg
of ELK-1 or ATF-2 fusion protein for the MAPK and p38 assays,
respectively. Incubation was performed at 301C for 30min at
1250r.p.m. and reactions were terminated with 25mlo f3  SDS
sample buffer. Samples were boiled at 1001C for 5min, centrifuged
at 10000r.p.m., 30ml was loaded onto a 4–12% Bis-tris (Novex)
gels in MOPS running buffer, transferred to a nitrocellulose
membrane (Nupage running buffer) and probed with Phospho-
ELK-1 or Phospho-ATF-2 primary antibody (1:1000) for MAPK
and p38, respectively. Visualisation with LumoGlo chemilumines-
cent reagent was performed following 1h incubation in 10ml
blocking buffer supplemented with horseradish peroxidase-con-
jugated anti-rabbit antibody (1:2000).
p53 assay
Treated cells were harvested in 1ml PBS, centrifuged and
supernatants were resuspended in 250ml urea lysis buffer for
30min on ice. Protein concentration was determined and 20mg
protein was separated and transferred as described above,
incubated for 1h in CM 1 primary antibody (1:1000) and detected
using chemiluminescence.
Table 1 Treatment regimens
MCF-7 breast cancer cells MDA-MB 468 breast cancer cells
Doxorubicin Vinorelbine Doxorubicin Vinorelbine
IC50 10mM 40mM 100nM 30mM
IC30 50nM 5n M FF
 MDA-MB-468 breast cancer cell line
MCF-7 breast cancer cell line 
ELK-1 
(40kDa)
 1    2  3    4   5    6  7    8 
1. Untreated  5. Vinorelbine 3 h
2. Doxorubicin 4 h 6. Doxorubicin and vinorelbine 
3. Pretreatment with doxorubicin  7. Doxorubicin 2 h
4. Doxorubicin 3 h 8. Pretreatment with vinorelbine
ELK-1
(40kDa)
 1   2    3   4    5   6    7    8  B
A
Figure 1 Western blot showing MAPK activity in MDA-MB-468 (A) and
MCF-7 (B) breast cancer cell lines treated with doxorubicin (IC50) and
vinorelbine (IC50) at different time points. Lane 1 shows untreated cells
(control); lanes 2 and 3 represent doxorubicin control (4h) and
pretreatment with doxorubicin followed by vinorelbine; Lanes 4 and 5
show doxorubicin and vinorelbine control for the combined doxorubicin
and vinorelbine treatment which is shown in lane 6; lanes 7 and 8 show
doxorubicin control and vinorelbine pretreatment respectively. The MAPK
activity was determined as previously described.
 MDA-MB-468 breast cancer cell line 
MCF-7 breast cancer cell line 
ATF-2
(38kDa)
1   2    3    4    5  6     7   8 
ATF-2
(38kDa)
1    2    3  4     5    6   7    8 
1. Untreated  5. Vinorelbine 3 h
2. Doxorubicin 4 h 6. Doxorubicin and vinorelbine 
3. Pretreatment with doxorubicin   7. Doxorubicin 2 h
4. Doxorubicin 3 h 8. Pretreatment with vinorelbine
B
A
Figure 2 Western blot showing p38 activity in MDA-MB-468 (A) and
MCF-7 (B) breast cancer cell lines treated with doxorubicin (IC50) and
vinorelbine (IC50) at different time points. Lane 1 shows untreated cells
(control); lanes 2 and 3 represent doxorubicin control (4h) and
pretreatment with doxorubicin followed by vinorelbine; Lanes 4 and 5
show doxorubicin and vinorelbine control for the combined doxorubicin
and vinorelbine treatment which is shown in lane 6; lanes 7 and 8 shows
doxorubicin control and vinorelbine pretreatment, respectively. The p38
activity was determined as previously described.
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Protein activity was quantified by scanning the films using
densitometry (Molecular Analyst). The activity was plotted as a
function of the fold increase of normalised area of kinase activity.
RESULTS
The MDA-MB-468 and MCF-7 breast cancer cell lines showed
constitutive MAPK and p38 activation (Figures 1 and 2).
Doxorubicin treatment did not affect MAPK nor p38 activity and
vinorelbine did not significantly affect MAPK activity.
However, vinorelbine elicited increased p38 activity (Figure 2,
lanes 3, 5, 6, 8). This occurred when vinorelbine was administered
as a single agent (Figure 2, lane 5), as pretreatment followed by
doxorubicin (Figure 2, lane 8) or given simultaneously with
doxorubicin (Figure 2, lane 6). Similar effects were demonstrated
when doxorubicin was administered prior to vinorelbine (Figure 2,
lane 3). Quantification of p38 activity using densitometry (Figure 3)
showed a two-fold increase of normalised area of p38 activity in
vinorelbine-treated MDA-MB-468 and MCF-7 cells compared to
the nonvinorelbine-treated cells (Figure 3, lanes 3, 5, 6, 8).
For p53 expression detected by the CM-1 antibody in the
MCF-7 breast cancer cell line (Figure 4, lanes 3, 5, 7, 9), p53
induction was noted following doxorubicin but not vinorelbine
treatment.
DISCUSSION
This study examined the effect of doxorubicin and vinorelbine
in vitro on the MAPK family and p53 pathways using two
breast cancer cell lines. The two drugs principally act via different
mechanisms: doxorubicin intercalates among DNA base pairs
resulting in conformational changes in DNA structure and
changes in the activity of topoisomerases, whereas vinorelbine is
known to disrupt microtubules in the mitotic spindle formation,
inducing metaphase arrest during mitosis (Perry, 1996). Consti-
tutive MAPK and p38 activity was confirmed in the MDA-MB-468
and MCF-7 breast cancer cell lines (Sivaraman et al, 1997; Hoshino
et al, 1999). However, when vinorelbine was administered,
increased p38 activity was shown in both cell lines. Whether this
was because of increased gene expression, increased translation or
post-translational modification is unclear. This effect was not seen
with doxorubicin, which appeared not to interfere with the p38
activity of vinorelbine. Under the same growth conditions,
increased p53 expression, but not enhanced p38 activity, was
demonstrated in MCF-7 when treated with doxorubicin, confirm-
ing a p53-mediated response to doxorubicin in cells containing a
wild-type p53 gene product (Bowcock, 1999; Roses, 1999;
Perego et al, 2001). While it has been suggested that cross-talk
may occur between p38 and p53 (Sanchez-Prieto et al,2 0 0 0 ) ,t h e
current data favour independent activity of p38 and p53 (Bacus et al,
2001). These in vitro findings provide a molecular basis for the
clinical response shown in patients treated with doxorubicin and
vinorelbine given in combination. Additivism, where doxorubicin
exerts its activity through the p53 pathway and vinorelbine through
the MAPK (p38) pathway may account, at least in part, for the high
clinical response rate.
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Figure 3 Quantification of p38 activity in MDA-MB-468 (A) and MCF-7
(B) breast cancer cell lines determined via densitometry following
treatment with doxorubicin (IC50) and vinorelbine (IC50). The y-axis
represents the fold increase of normalised area of p38 activity. The x-axis
displays the untreated cells (lane 1); doxorubicin control (4h) and
doxorubicin pre treatment followed by vinorelbine (lanes 2 and 3); the 3h
doxorubicin and vinorelbine treatment (lanes 4 and 5) and combined
doxorubicin and vinorelbine treatment (lane 6); doxorubicin (2h) and
vinorelbine pretreatment follwed by doxorubicin is shown in lanes 7 and 8.
 MCF-7 breast cancer cell line 
 MCF-7 breast cancer cell line 
 p53 
1   2   3   4    5   6    7    8   9 
Actin 
1. p53 control
2. Untreated 4 h
3. Doxorubicin 4 h
4. Vinorelbine 4 h
5. Doxo+vino 4 h 
A
B
6. Untreated 24 h
7. Doxorubicin 24 h
8. Vinorelbine 24 h
9. Doxo+vino 24 h
Figure 4 Western blot showing changes in p53 expression in MCF-7
breast cancer cell line following doxorubicin (IC30) and vinorelbine (IC30)
treatment at 4 and 24h (A). A measure of 20mg protein was loaded. Lane
1 represents p53 control Sf 9 cells. Lanes 2 and 6 show the untreated cells
for 4 and 24h respectively. Single doxorubicin or vinorelbine treatment for
4 and 24h displayed in lanes 3, 4, 7 and 8, is respectively, and combined
treatment for 4 and 24h shown in lanes 5 and 9. Following treatment, cells
were lysed, protein concentration was determined and p53 expression was
visualised using Western blotting. Membranes were probed using CM-1
antibody. Probing for actin showed equal loading (B).
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